CIBC Asset Management Inc lowered its holdings in shares of Thermo Fisher Scientific Inc (NYSE:TMO) by 9.2% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 77,469 shares of the medical research company’s stock after selling 7,890 shares during the period. CIBC Asset Management Inc’s holdings in Thermo Fisher Scientific were worth $13,516,000 as of its most recent SEC filing.

A number of other large investors have also modified their holdings of the stock. Sharkey Howes & Javer boosted its stake in Thermo Fisher Scientific by 1.0% during the 1st quarter. Sharkey Howes & Javer now owns 733 shares of the medical research company’s stock worth $113,000 after purchasing an additional 7 shares during the period. Beacon Trust Co. boosted its stake in Thermo Fisher Scientific by 0.6% during the 1st quarter. Beacon Trust Co. now owns 2,159 shares of the medical research company’s stock worth $341,000 after purchasing an additional 12 shares during the period. Dumont & Blake Investment Advisors LLC boosted its stake in Thermo Fisher Scientific by 0.3% during the 1st quarter. Dumont & Blake Investment Advisors LLC now owns 5,526 shares of the medical research company’s stock worth $849,000 after purchasing an additional 15 shares during the period. Reinhart Partners Inc. boosted its stake in Thermo Fisher Scientific by 0.6% during the 2nd quarter. Reinhart Partners Inc. now owns 3,430 shares of the medical research company’s stock worth $598,000 after purchasing an additional 20 shares during the period. Finally, Azimuth Capital Management LLC boosted its stake in Thermo Fisher Scientific by 0.8% during the 1st quarter. Azimuth Capital Management LLC now owns 3,210 shares of the medical research company’s stock worth $493,000 after purchasing an additional 25 shares during the period. Hedge funds and other institutional investors own 83.52% of the company’s stock.

In other Thermo Fisher Scientific news, Director Jim P. Manzi sold 11,318 shares of the business’s stock in a transaction dated Friday, August 18th. The shares were sold at an average price of $172.94, for a total value of $1,957,334.92. Following the sale, the director now directly owns 38,757 shares in the company, valued at $6,702,635.58. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director C Martin Harris sold 360 shares of the business’s stock in a transaction dated Wednesday, August 30th. The stock was sold at an average price of $180.97, for a total transaction of $65,149.20. Following the completion of the sale, the director now owns 5,312 shares in the company, valued at $961,312.64. The disclosure for this sale can be found here. Over the last quarter, insiders sold 22,738 shares of company stock worth $4,021,512. 0.49% of the stock is owned by company insiders.

Thermo Fisher Scientific Inc (NYSE TMO) opened at 191.63 on Friday. The stock has a 50 day moving average of $178.31 and a 200-day moving average of $169.32. The stock has a market cap of $74.76 billion, a P/E ratio of 33.39 and a beta of 1.05. Thermo Fisher Scientific Inc has a one year low of $139.07 and a one year high of $192.28.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings data on Wednesday, July 26th. The medical research company reported $2.30 earnings per share for the quarter, topping the consensus estimate of $2.27 by $0.03. The business had revenue of $5 billion during the quarter, compared to the consensus estimate of $4.92 billion. Thermo Fisher Scientific had a net margin of 11.80% and a return on equity of 15.97%. The company’s quarterly revenue was up 10.2% compared to the same quarter last year. During the same quarter in the prior year, the company posted $2.03 earnings per share. Analysts anticipate that Thermo Fisher Scientific Inc will post $9.35 EPS for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Monday, October 16th. Shareholders of record on Friday, September 15th will be given a $0.15 dividend. This represents a $0.60 annualized dividend and a yield of 0.31%. The ex-dividend date of this dividend is Thursday, September 14th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 10.45%.

TMO has been the subject of a number of recent research reports. Bank of America Corporation reiterated a “buy” rating and set a $210.00 price target (up previously from $200.00) on shares of Thermo Fisher Scientific in a research note on Friday, July 21st. Zacks Investment Research cut shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research note on Monday, July 31st. Cantor Fitzgerald initiated coverage on shares of Thermo Fisher Scientific in a research note on Thursday, May 18th. They issued an “overweight” rating and a $194.00 target price for the company. BidaskClub cut shares of Thermo Fisher Scientific from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 31st. Finally, Cowen and Company restated a “buy” rating and issued a $200.00 target price on shares of Thermo Fisher Scientific in a research note on Friday, September 1st. One analyst has rated the stock with a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average price target of $191.94.

TRADEMARK VIOLATION NOTICE: “CIBC Asset Management Inc Sells 7,890 Shares of Thermo Fisher Scientific Inc (TMO)” was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this report on another website, it was copied illegally and reposted in violation of US and international copyright legislation. The correct version of this report can be accessed at https://www.thecerbatgem.com/2017/09/10/cibc-asset-management-inc-sells-7890-shares-of-thermo-fisher-scientific-inc-tmo.html.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Stock Ratings for Thermo Fisher Scientific Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific Inc and related stocks with our FREE daily email newsletter.